Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis

T. MurayaM.A., Oren M. Tepper, T. Asahara

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

While neovascularization plays an integral role in atherosclerosis, stimulation of angiogenesis does not appear to promote atherogenesis. This observation is important in view of recent advancements in angiogenic gene and cell therapy aimed at promoting new blood vessel growth in humans with vascular disease. Endothelial progenitor cells (EPCs) may actually prevent rather than provoke intimal thickening and vascular remodeling by promoting re-endothelialization in response to vascular trauma, as occurs with percutaneous transluminal vascular intervention for treating atherosclerotic vessels. Further support for the hypothesis that EPCs continuously repair vascular injury and contribute to the rejuvenation of vessels has been derived from animal studies demonstrating that serial injection of bone marrow-derived EPCs prevent atherogenesis, but that the quantity and quality of these cells deteriorate with aging. This chapter provides a summary of the influence of angiogenesis on atheromatous disease. Furthermore, the increasingly important relationship between atherosclerosis and newly emerging techniques in therapeutic angiogenesis (i.e., gene therapy and cell therapy with EPCs) is discussed.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages777-783
Number of pages7
Volume170
DOIs
StatePublished - 2005
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume170
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Endothelial cells
Atherosclerosis
Stem Cells
Blood Vessels
Cell- and Tissue-Based Therapy
Genetic Therapy
Tunica Intima
Rejuvenation
Gene therapy
Vascular System Injuries
Blood vessels
Vascular Diseases
Bone
Animals
Repair
Genes
Aging of materials
Bone Marrow
Injections
Endothelial Progenitor Cells

Keywords

  • Atherosclerosis
  • Endothelial progenitor cells
  • Neovascularization
  • Vascular injury

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

MurayaM.A., T., Tepper, O. M., & Asahara, T. (2005). Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis. In Handbook of Experimental Pharmacology (Vol. 170, pp. 777-783). (Handbook of Experimental Pharmacology; Vol. 170). https://doi.org/10.1007/3-540-27661-0-29

Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis. / MurayaM.A., T.; Tepper, Oren M.; Asahara, T.

Handbook of Experimental Pharmacology. Vol. 170 2005. p. 777-783 (Handbook of Experimental Pharmacology; Vol. 170).

Research output: Chapter in Book/Report/Conference proceedingChapter

MurayaM.A., T, Tepper, OM & Asahara, T 2005, Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis. in Handbook of Experimental Pharmacology. vol. 170, Handbook of Experimental Pharmacology, vol. 170, pp. 777-783. https://doi.org/10.1007/3-540-27661-0-29
MurayaM.A. T, Tepper OM, Asahara T. Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis. In Handbook of Experimental Pharmacology. Vol. 170. 2005. p. 777-783. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/3-540-27661-0-29
MurayaM.A., T. ; Tepper, Oren M. ; Asahara, T. / Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis. Handbook of Experimental Pharmacology. Vol. 170 2005. pp. 777-783 (Handbook of Experimental Pharmacology).
@inbook{33934381f36840e2bc22d3c5d5ddb878,
title = "Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis",
abstract = "While neovascularization plays an integral role in atherosclerosis, stimulation of angiogenesis does not appear to promote atherogenesis. This observation is important in view of recent advancements in angiogenic gene and cell therapy aimed at promoting new blood vessel growth in humans with vascular disease. Endothelial progenitor cells (EPCs) may actually prevent rather than provoke intimal thickening and vascular remodeling by promoting re-endothelialization in response to vascular trauma, as occurs with percutaneous transluminal vascular intervention for treating atherosclerotic vessels. Further support for the hypothesis that EPCs continuously repair vascular injury and contribute to the rejuvenation of vessels has been derived from animal studies demonstrating that serial injection of bone marrow-derived EPCs prevent atherogenesis, but that the quantity and quality of these cells deteriorate with aging. This chapter provides a summary of the influence of angiogenesis on atheromatous disease. Furthermore, the increasingly important relationship between atherosclerosis and newly emerging techniques in therapeutic angiogenesis (i.e., gene therapy and cell therapy with EPCs) is discussed.",
keywords = "Atherosclerosis, Endothelial progenitor cells, Neovascularization, Vascular injury",
author = "T. MurayaM.A. and Tepper, {Oren M.} and T. Asahara",
year = "2005",
doi = "10.1007/3-540-27661-0-29",
language = "English (US)",
isbn = "9783540225690",
volume = "170",
series = "Handbook of Experimental Pharmacology",
pages = "777--783",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Reciprocal role of vasculogenic factors and progenitor cells in atherogenesis

AU - MurayaM.A., T.

AU - Tepper, Oren M.

AU - Asahara, T.

PY - 2005

Y1 - 2005

N2 - While neovascularization plays an integral role in atherosclerosis, stimulation of angiogenesis does not appear to promote atherogenesis. This observation is important in view of recent advancements in angiogenic gene and cell therapy aimed at promoting new blood vessel growth in humans with vascular disease. Endothelial progenitor cells (EPCs) may actually prevent rather than provoke intimal thickening and vascular remodeling by promoting re-endothelialization in response to vascular trauma, as occurs with percutaneous transluminal vascular intervention for treating atherosclerotic vessels. Further support for the hypothesis that EPCs continuously repair vascular injury and contribute to the rejuvenation of vessels has been derived from animal studies demonstrating that serial injection of bone marrow-derived EPCs prevent atherogenesis, but that the quantity and quality of these cells deteriorate with aging. This chapter provides a summary of the influence of angiogenesis on atheromatous disease. Furthermore, the increasingly important relationship between atherosclerosis and newly emerging techniques in therapeutic angiogenesis (i.e., gene therapy and cell therapy with EPCs) is discussed.

AB - While neovascularization plays an integral role in atherosclerosis, stimulation of angiogenesis does not appear to promote atherogenesis. This observation is important in view of recent advancements in angiogenic gene and cell therapy aimed at promoting new blood vessel growth in humans with vascular disease. Endothelial progenitor cells (EPCs) may actually prevent rather than provoke intimal thickening and vascular remodeling by promoting re-endothelialization in response to vascular trauma, as occurs with percutaneous transluminal vascular intervention for treating atherosclerotic vessels. Further support for the hypothesis that EPCs continuously repair vascular injury and contribute to the rejuvenation of vessels has been derived from animal studies demonstrating that serial injection of bone marrow-derived EPCs prevent atherogenesis, but that the quantity and quality of these cells deteriorate with aging. This chapter provides a summary of the influence of angiogenesis on atheromatous disease. Furthermore, the increasingly important relationship between atherosclerosis and newly emerging techniques in therapeutic angiogenesis (i.e., gene therapy and cell therapy with EPCs) is discussed.

KW - Atherosclerosis

KW - Endothelial progenitor cells

KW - Neovascularization

KW - Vascular injury

UR - http://www.scopus.com/inward/record.url?scp=33645792633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645792633&partnerID=8YFLogxK

U2 - 10.1007/3-540-27661-0-29

DO - 10.1007/3-540-27661-0-29

M3 - Chapter

C2 - 16596823

AN - SCOPUS:33645792633

SN - 9783540225690

VL - 170

T3 - Handbook of Experimental Pharmacology

SP - 777

EP - 783

BT - Handbook of Experimental Pharmacology

ER -